Using Atovaquone to treat platinum-resistant ovarian cancer
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
This study is testing if atovaquone, a medication usually used for infections, can help people with platinum-resistant ovarian cancer live longer and feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Emory University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Atlanta, Georgia) |
| Trial ID | NCT05998135 on ClinicalTrials.gov |
What this trial studies
This phase II trial evaluates the effectiveness of atovaquone, a medication typically used for treating infections, in patients with platinum-resistant ovarian cancer. The study aims to determine the progression-free survival of participants and assess clinical benefits such as response rates and overall survival. Patients will receive atovaquone orally and undergo imaging and biopsies to monitor their condition throughout the trial. The study also investigates the drug's impact on tumor immune response and specific gene transcription.
Who should consider this trial
Good fit: Ideal candidates are adults with platinum-resistant high-grade serous ovarian cancer who have experienced disease progression within six months of their last platinum-based chemotherapy.
Not a fit: Patients under 18, pregnant or breastfeeding individuals, and those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with limited choices due to platinum resistance.
How similar studies have performed: While the use of atovaquone for this indication is novel, other studies have explored repurposing existing medications for cancer treatment with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * There will be no limitations on number of prior lines of therapy * Trial is open to non-English speaking patients * Trial is open to patients referred from community practice Exclusion Criteria: * Patients who are \< 18 years old * Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive) * Patients who are incarcerated * Patients who are unable to provide consent / lack decision-making capacity
Where this trial is running
Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Namita Khanna, MD, MSPH — Emory University Hospital/Winship Cancer Institute
- Study coordinator: Namita Khanna, MD, MSPH
- Email: namita.khanna@emory.edu
- Phone: 404-778-3401
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.